AaiPharma “Unusual Sales” May Prompt Subpoenas; CEO Steps Down
Executive Summary
An investigation into sales of aaiPharma products may result in subpoenas from the Securities & Exchange Commission and the U.S. Attorney's Office, the company said
You may also be interested in...
AaiPharma inquiry
AaiPharma may delay filing its Form 10-K while an independent committee investigates "unusual sales" for the bronchodilatorBrethine and pain agent Darvocet...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: